ProCE Banner Activity

Phase IIb Protocol 011 Safety Analysis at Week 96: Islatravir Plus Doravirine Following Islatravir, Doravirine, Lamivudine Induction

Slideset Download
Conference Coverage
After 24 weeks of 3-drug induction therapy in treatment-naive patients, islatravir plus doravirine dual therapy was generally well tolerated through 96 weeks.

Released: July 20, 2021

Expiration: July 19, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner